USP21

Ubiquitin carboxyl-terminal hydrolase 21 · Q9UK80 · USP21 on Sugi Atlas →

271 patent compounds predicted against USP21, 81 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL18321066 SCHEMBL18321066 0.57 10/20
SCHEMBL5173078 SCHEMBL5173078 0.60 5/20
SCHEMBL7445861 SCHEMBL7445861 0.46 5/20
SCHEMBL7445870 SCHEMBL7445870 0.46 5/20
SCHEMBL12168554 SCHEMBL12168554 0.46 5/20
SCHEMBL24843482 SCHEMBL24843482 0.38 4/20
SCHEMBL22305742 SCHEMBL22305742 0.33 4/20
SCHEMBL1168058 SCHEMBL1168058 0.44 3/20
SCHEMBL5349521 SCHEMBL5349521 0.38 3/20
SCHEMBL4845074 SCHEMBL4845074 0.35 3/20
SCHEMBL4843020 SCHEMBL4843020 0.34 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4843515) 0.34 3/20
SCHEMBL26758070 SCHEMBL26758070 0.46 2/20
SCHEMBL6585794 SCHEMBL6585794 0.46 2/20
SCHEMBL27546176 SCHEMBL27546176 0.46 2/20
SCHEMBL3467279 SCHEMBL3467279 0.44 2/20
SCHEMBL6583446 SCHEMBL6583446 0.42 2/20
SCHEMBL5349489 SCHEMBL5349489 0.40 2/20
SCHEMBL5353449 SCHEMBL5353449 0.40 2/20
SCHEMBL6580207 SCHEMBL6580207 0.39 2/20

Clinical trials — most relevant to USP21 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome PHASE3COMPLETED
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults PHASE3WITHDRAWN
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1) PHASE3NOT_YET_RECRUITING
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine PHASE2/PHASE3WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection PHASE2WITHDRAWN
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants PHASE1COMPLETED
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 PHASE1COMPLETED
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines. PHASE1WITHDRAWN
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
The Danish TURNER Cryopreservation Study nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
A Natural History Study of Angelman Syndrome nanRECRUITING
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2 nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome nanCOMPLETED
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness nanRECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a USP21 binder may also engage these)

ProteinNameSimilarity
Q2KJ72 1.000 Q2KJ72 →
B2GUX4 1.000 B2GUX4 →
Q9QZL6 1.000 Q9QZL6 →
USP20 Ubiquitin carboxyl-terminal hydrolase 20 0.978 landscape →
A7Z056 0.975 A7Z056 →
Q7ZUM8 0.974 Q7ZUM8 →
Q9JLG8 0.974 Q9JLG8 →
Q5XGZ2 0.973 Q5XGZ2 →
Q9P2H5 0.973 Q9P2H5 →
Q8C6M1 0.973 Q8C6M1 →
A5PN09 0.972 A5PN09 →
Q8BL80 0.972 Q8BL80 →
Q7Z5H3 0.972 Q7Z5H3 →
Q0QWG9 0.970 Q0QWG9 →
A0JM59 0.970 A0JM59 →
Q62925 0.969 Q62925 →
P98174 0.969 P98174 →
Q8C2S0 0.969 Q8C2S0 →
A0FI79 0.969 A0FI79 →
A4D2P6 0.969 A4D2P6 →
Q8BUM9 0.969 Q8BUM9 →
Q5R5Z6 0.969 Q5R5Z6 →
GRB7 Growth factor receptor-bound protein 7 0.968 landscape →
P78524 0.968 P78524 →
P52734 0.968 P52734 →
Q70CQ4 0.967 Q70CQ4 →
Q6NS60 0.967 Q6NS60 →
Q6NTR6 0.967 Q6NTR6 →
O75808 0.966 O75808 →
Q99MU3 0.966 Q99MU3 →